Keros Therapeutics (KROS) announced the appointment of Yung Chyung, M.D., as Keros’ Chief Medical Officer, CMO, effective as of November 1, 2024. Chyung is joining the Company after most recently serving as Executive Vice President and Chief Medical Officer of Tourmaline Bio (TRML) from August 2022 to October 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics initiated with an Outperform at Scotiabank
- 3 Best Stocks to Buy Now, 9/23/2024, According to Top Analysts
- Keros Therapeutics initiated with a Buy at Guggenheim
- Keros Therapeutics price target lowered to $76 from $81 at BofA
- Keros Therapeutics closes screening for Phase 2 trial of cibotercept